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Interaction of heterotrimeric G13 protein with an A-kinase-
anchoring protein 110 (AKAP110) mediates
cAMP-independent PKA activation
Jiaxin Niu*, Rita Vaiskunaite*, Nobuchika Suzuki*, Tohru Kozasa*,
Daniel W. Carr†, Nickolai Dulin* and Tatyana A. Voyno-Yasenetskaya*
Heterotrimeric G proteins [1] and protein kinase A Results and discussion
G13 interacts with A-kinase-anchoring protein 110(PKA) are two important transmitters that transfer
(AKAP110) in a yeast two-hybrid screensignals from a wide variety of cell surface receptors
Todiscover novel proteins thatmight participate in signal-to generate physiological responses. The
ing via heterotrimeric G proteins, a two-hybrid screen wasestablished mechanism of PKA activation involves
performed on a human testis library using G13 as bait.the activation of the Gs-cAMP pathway [2]. Binding
Because effector molecules interact with high affinity toof cAMP to the regulatory subunit of PKA (rPKA)
the GTP-bound G subunits, we have used the activatedleads to a release and subsequent activation of a
form of G13 (G13Q226L) as bait. One of the positivecatalytic subunit of PKA (cPKA). Here, we report a
clones from this screen was purified, sequenced, andnovel mechanism of PKA stimulation that does not
identified as a fragment of A-kinase-anchoring protein,require cAMP. Using yeast two-hybrid screening, we
AKAP110 (aa 683–853). AKAP110 was cloned recentlyfound that the  subunit of G13 protein interacted
and was initially found in sperm cells [3]. Since then,with a member of the PKA-anchoring protein family,
AKAP110 (and G13) was detected in the granular andAKAP110. Using in vitro binding and
Purkinje neurons of the cerebellum by Western blotting,coimmunoprecipitation assays, we have shown that
indirect immunostaining, immunofluorescence, and RT-only activated G13 binds to AKAP110, suggesting
PCR studies (D.Carr andT. Voyno-Yasenetskaya, unpub-a potential role for AKAP110 as a G subunit effector
lished data). To determine the specificity of the interac-protein. Importantly, G13, AKAP110, rPKA, and
tion of G13 with AKAP110, plasmids containing domaincPKA can form a complex, as shown by
fragments of AKAP110 were transformed together withcoimmunoprecipitation. By characterizing the
either G13 or G12 into the yeast reporter strain EGY48,functional significance of the G13-AKAP110
and cotransformants were selected for -galactosidase ac-interaction, we have found that G13 induced
tivity at 30C for 4 days. -galactosidase activity data indi-release of the cPKA from the AKAP110-rPKA
cated that G13, but not G12, interacted with thecomplex, resulting in a cAMP-independent PKA
AKAP110 fragments (Figure 1a). The absence of interac-activation. Finally, AKAP110 significantly
tion between AKAP110 and G12 was specific, becausepotentiated G13-induced activation of PKA. Thus,
the same construct was used in the similar yeast two-AKAP110 provides a link between heterotrimeric G
hybrid screen that yielded eight different positive clonesproteins and cAMP-independent activation of PKA.
coding for novel G12-interacting proteins (R. Vaisku-
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G13. Thus, our data show that G13 specifically inter-
acts with the C-terminal domain of AKAP110.
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hydrolysis [4]. These data suggest that AKAP110 may
function as a G subunit effector protein.
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Figure 1
G13 interacts with AKAP110. (a) A specific interaction of AKAP110 beads were pulled down by centrifugation, and bound G13 was
with G13 in yeast two-hybrid system. pB42AD constructs separated by SDS-PAGE and immunoblotted with antibody against
containing full-length (AKAP-FL), 1–683 aa (AKAP-N) regions, and G13. C-350, C-terminal 350 amino acids; FL, full-length AKAP10.
685–853 aa (AKAP-C) regions of AKAP110 as indicated were (d) PKA, AKAP110, and G13 form a protein complex in vivo.
transformed into yeast reporter strain EGY48 either with or without Coimmunoprecipitation of AKAP110 with G13. HEK-293 cells grown
pLexA-G13Q226L or pLexA-G12Q229L. Cotransformants were in 10-cm2 dishes were transiently transfected with vector alone or
selected and underwent a -galactosidase assay. The blue color with various Myc-tagged constructs of AKAP110 together with wild-
indicates a protein-protein interaction. (b) The domain structure of type HA-tagged G13. A total of 48 hr after transfection, cells were
AKAP110. The domain that binds the regulatory subunit II of PKA, lysed, an equal amount of cell lysates was immunoprecipitated with
the RII binding domain, is located between amino acids 124 and 141 agarose-conjugated anti-Myc antibodies in the presence or absence
[3]. The putative G13 binding domain is located at 685–853 aa. of AlF4. Immunoprecipitates and cell lysates were analyzed by
(c) Direct interaction of purified G13 protein with AKAP110 GST Western blotting using antibodies against Myc or HA. (e)
fusion proteins in vitro. 1 M purified GST or GST-AKAP110 fusion Coimmunoprecipitation of AKAP110 with endogenous rPKA. The
proteins bound to glutathione-sepharose beads were mixed with 0.25 same immunoprecipitates were probed with Myc antibodies or
M purified G13-GDP in 100 l binding buffer to perform an in antibodies against RII. All experiments (b–e) were performed 3–4
vitro binding assay as described in the Materials and methods. times with similar results.
Where indicated, AlF4 was added. Glutathione-sepharose
G13 and AKAP110 form a protein complex in intact cells and C-350 were 1:4. Thus, it is likely that apparently
weak interactions could be a result of lower expressionTo assess the in vivo interaction, we assayed the physical
association between G13 and AKAP110 by coimmuno- or stability of C-terminal domains of AKAP110. Both short
(685–853 aa) and long (503–853 aa) C-terminal fragments,precipitation from human kidney embryonic 293 (HEK-
293) cells transfected with Myc-tagged AKAP110 con- but not N-terminal (1–500 aa and 1–350 aa) fragments,
bind to G13. The ability of the N-terminal domain tostructs and HA-tagged G13. Western blotting showed
that the expression of full-length AKAP110 is higher than interact with the RII subunit was performed as a positive
control for the N-terminal domain activity (see the Sup-the expression of any AKAP110 construct (Figure 1e). As
it is not unusual for protein domains to be less stable than plementary material available with this article online).
Thus, we have mapped the G13 binding site of AKAP110full-length protein, we have determined relative intensi-
ties of the immunoprecipitated G13 and AKAP110 con- to a region between residues 685 and 853 (Figure 1e).
Consistent with results from the two-hybrid screen andstructs’ bands by densitometry using ImageQuant soft-
ware. The ratios of G13 to AKAP110 full-length, C-170, in vitro binding, full-length AKAP110 bound only to an
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Figure 2AlF4-induced active state of G13. Additionally, AKAP110
interacted with the endogenous RII subunit. Interest-
ingly, interaction of the G13 with AKAP110 did not
affect the interaction of RII with AKAP110 (Figure 1f).
These data suggest that AKAP110 can interact simultane-
ously with RII and G13 proteins and that G13 binding
does not affect RII binding to AKAP110.
AKAP110 does not regulate GTPase activity or rate
or nucleotide exchange activity
Some effector proteins, such as phospholipase C and
cGMP phosphodiesterase  subunit, also act as GTPase-
activating proteins (GAPs) that accelerate deactivation of
heterotrimeric G proteins [5, 6]. Therefore, we tested
whether AKAP110 affects the ability of G13 to hydrolyze
GTP. AKAP110 did not stimulate GTPase activity of
G13 over the untreated control (Figure 2a). The positive
control, p115RhoGEF, significantly stimulated GTPase
activity at all time points. We also tested whether
AKAP110 can regulate the rate of nucleotide exchange
of G13 protein. In the absence of a receptor, the rate-
limiting step for binding of the nonhydrolyzable GTP
analog GTPS to the G protein is the release of GDP.
The full-length AKAP110 did not affect GTPS binding
by G13 (Figure 2b). Therefore, AKAP110 does not regu-
late GTPase activity or rate or nucleotide exchange ac-
tivity.
Rho guanine nucleotide exchange factor, p115RhoGEF,
is a recently identified G13 effector. G13 directly stim-
ulates p115RhoGEF, leading to Rho activation [7, 8]. We
next tested whether AKAP110 could affect the guanine
nucleotide exchange of Rho protein. Consistent with pre-
AKAP does not affect either guanine nucleotide binding to G13 orvious reports, p115RhoGEF induced GTPS binding to
the GTPase activity of G13. (a) The GTPase activity of G13 wasRho. This effect increased in the presence of AlF4-acti- assayed in the presence of 400 nM full-length AKAP110 (closed
vated G13. However, AKAP110 did not affect GTPS circles) or 20 nM p115 RhoGEF (open square) or control, GST
protein (open circles). (b) Binding of GTPS to G13 (100 nM) wasbinding by Rho (data not shown). Although many G13-
performed by incubating the proteins at 30C for 60 min in theinduced signaling events are Rho dependent, it appears
presence or absence of 500 nM full-length AKAP110. All experimentsunlikely that AKAP110 is involved in G13-induced Rho (a,b) were performed 2–3 times with similar results.
activation.
G13 induces release of the PKA catalytic subunit
from the AKAP110-RII complex fected the increasing concentrations of constitutively acti-
vated G13. Interestingly, both PKA activity and theTo investigate the functional consequences of the interac-
tion between AKAP110 and G13 in a heterologous ex- amount of cPKA associated with AKAP110 was decreased,
while the amount of RII detected by Western blotting didpression system, HEK-293 cells were transfected with
cDNAs for AKAP110 (tagged with MYC) and were G13 not change in the presence of G13Q226L (Figure 3a).
Importantly, wild-type G13 did not affect PKA activitytagged with an HA epitope. Expression of AKAP110 and
G13 did not change the amount of endogenous cPKA associated with AKAP110 (Figure 3a). Only G13Q226L,
but not GiQ205L or G12Q229L, reduced PKA activityor rPKA, as determined by Western blotting of total cell
lysates (data not shown). Both endogenous rPKA and associated with AKAP110, indicating that this effect by
G13 is specific (Figure 3b).cPKA coprecipitated with AKAP110 (Figure 3a). PKA
catalytic activity in immunoprecipitated material was de-
termined in the absence or presence of 0.5 mM cAMP. To confirm the observation that G13 induces the release
of cPKA from the AKAP110 complex, AKAP110 was im-PKA activity was defined as the activity inhibited by 4M
PKA inhibitor PKI (Figure 3a) and was enriched by 58.4 munoprecipitated from HEK-293 cells transiently trans-
fected with Myc-tagged AKAP110. Preincubation of the5-fold in the presence of cAMP (n  7). We then cotrans-
Brief Communication 1689
Figure 3
G13 induces the release of the PKA catalytic subunit from the presence of 0.5 mM cAMP or AlF4-activated G13 at 30C for 30
AKAP110-RII complex. (a) Coprecipitation of PKA with AKAP110. min, and the reactions were terminated by centrifugation. Both beads
HEK-293 cells were cotransfected with Myc-tagged AKAP110 and and supernatant were analyzed by Western blot using antibodies
different amounts of G13Q226L or G13-wt as indicated, and against Myc, RII, or cPKA. (d) G13 specifically stimulated PKA
were then immunoprecipitated with anti-Myc antibody. activity in vitro. AKAP110 was immunoprecipitated from transiently
Immunoprecipitated material was incubated in the absence (basal) transfected HEK-293 cells as described above. Immunoprecipitates
or presence (cAMP) of 0.5 mM cAMP and was assayed for kinase were incubated in 40 l kinase buffer in the presence of AlF4-activated
activity. As a control, the plus cAMP samples were also assayed in G13 or AlF4-activated Gi at 30C for 30 min and were assayed
the presence of 4 M PKA inhibitor PKI (cAMP 	 PKI). Values are for kinase activity as described in the Materials and methods. (e)
expressed as means  SEM of seven separate experiments. The G13Q226QL does not affect cAMP levels. HEK-293 cells were
presence of cPKA and RII in immunoprecipitates was detected by cotransfected with either empty vector, activated GsR145C,
Western blot. (b) G13Q226L specifically decreased PKA activity activated G13Q226L, or full-length AKAP110. The cells were then
associated with AKAP110. HEK-293 cells were transiently transfected labeled with [3H]adenine and were subjected to cAMP assay as
with Myc-tagged AKAP110 together with either vector alone, described in the Materials and methods. (f) AKAP110 potentiates
GiQ205L, G12Q229L, or G13Q226L as indicated. They were G13-induced VASP phosphorylation. Flag-tagged VASP was
then lysed and immunoprecipitated with Myc antibodies, followed by cotransfected with GsR145C, G13Q226L, or AKAP110 as
measurement of the PKA activity associated with AKAP110. (c) AlF4- indicated. Cells were lysed, and the phosphorylation-dependent
stimulated G13 induces the release of cPKA from the PKA- electrophoretic mobility shift of VASP was determined by
AKAP110 complex in vitro. AKAP110 was immunoprecipitated from immunoblotting cell lysates with FLAG antibodies. All experiments
transiently transfected HEK-293 cells as described above. (b–f) were performed 3–4 times with similar results.
Immunoprecipitates were incubated in 40 l kinase buffer in the
immunocomplexes with 0.5 mM cAMP induced the re- PKA-specific activity stimulated with 0.2 M G13 was
6 pmol/min/U cPKA. These data suggest that purifiedlease of cPKA bound to rPKA into the supernatant (Figure
3c). This release was accompanied by a dramatic increase recombinant G13 can induce the release of catalytic
subunits from the PKA-AKAP110 complex. This G13-in PKA activity (Figure 3a). Preincubation of the immuno-
complexes with AlF4-activated G13 also induced the induced release of the catalytic subunit of PKA from the
regulatory subunit of PKA did not require cAMP.release of cPKA, as determined by Western blotting and
increased kinase activity (Figure 3c,d). In a control experi-
ment, Gi2 did not affect PKA associated with AKAP110 Based on this data, we postulated that theG13-AKAP110
complex would enhance the cAMP-independent phos-immunocomplexes (Figure 3d).We have quantitated rela-
tive PKA-specific activity as pmol of phosphate incorpo- phorylation of PKA substrates. The established mecha-
nism of PKA activation in response to various hormonesrated into the PKA substrate malantide per minute per
unit of immunoprecipitated cPKA. An arbitrary unit of involves stimulatory G proteins, Gs, which activate ade-
nylyl cyclase, resulting in the production of cAMP. Bind-immunoprecipitated cPKA was determined by Western
blotting, followed by densitometry. PKA activity was de- ing of cAMP to rPKA leads to the release and activation
of cPKA [2]. However, we have previously reported thattermined as activity inhibited by 4 M PKI. The half-
maximal PKA-specific activity stimulated with 0.5 mM G13 does not induce the production of intracellular
cAMP in HEK-293 cells [9]. This observation was con-cAMP was 60 pmol/min/U cPKA, and the half-maximal
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Figure 4 Another interesting possibility is that signal specificity
is achieved (in addition to other mechanisms) via the
interaction of ubiquitous signaling molecules with tissue-
specific signaling molecules. Such signal specificity is
probably the case in the G13-AKAP110 interaction, in
which G13 is ubiquitously expressed, and AKAP110 ex-
pression is restricted to a few cell types. Thus, based on
data showing that G13 regulates the actin cytoskeleton
and that disruption of the AKAP110-PKA interaction
blocks the sperm motility, we predict that the G13-
AKAP110 interaction could be important in the regulation
of sperm motility. An additional important physiological
question about the role of the G13-AKAP110 interaction
in the cerebellar neurons is based on data showing that
G13 induces growth cone collapse in neuronal cell lines
and AKAP110 is located in cerebellum neurons. Finally,
a major challenge for future studies is to determine the
molecular mechanism of G13-dependent release of
cPKA from the AKAP110-RII complex.
Supplementary materialA proposed model for G protein activation of PKA. Activated G13
Supplementary material including the Materials and methods, whichbinds to AKAP110 and induces the release of the catalytic subunit from
includes details concerning yeast two-hybrid screening, protein puri-the regulatory II subunit of PKA.
fication, in vitro binding assay, immunoprecipitation, and Western
blotting, [35S]GTPS binding assay, gap assay, cyclic AMP assay, in
vitro kinase assay, and PKA activity in intact cells, is available at http://
images.cellpress.com/supmat/supmatin.htm.
firmed by determining cAMP levels in HEK-293 cells
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